Rating On Watch: SciClone Pharma (SCLN) Is Now Covered By Maxim Group. What to Expect?

November 29, 2016 - By Richard Conner

Rating On Watch: SciClone Pharma (SCLN) Is Now Covered By Maxim Group. What to Expect?

Why Maxim Group Gives SciClone Pharma (SCLN) $14.0 Price Target

In a an analyst report shared with investors on Tuesday, 29 November, Maxim Group analyst just started coverage of SciClone Pharma (SCLN) with “Buy” rating. The price target is exactly $14.0.

The stock increased 0.49% or $0.05 during the last trading session, hitting $10.25. SciClone Pharmaceuticals, Inc. (SCLN) has declined 22.11% since April 26, 2016 and is downtrending. It has underperformed by 27.37% the S&P500.

Analysts await SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) to report earnings on March, 9.

Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.16, from 1.18 in 2016Q1. The ratio is positive, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

Legal And General Gru Plc holds 8,660 shares or 0% of its portfolio. Fisher Asset Mngmt Limited Liability last reported 0.01% of its portfolio in the stock. The Quebec – Canada-based Sector Pension Inv Board has invested 0% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). New York State Common Retirement Fund has invested 0% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Gsa Capital Llp accumulated 209,113 shares or 0.15% of the stock. Acadian Asset Limited Liability Corp accumulated 0.13% or 1.99 million shares. California Pub Employees Retirement Sys owns 135,200 shares or 0% of their US portfolio. Comml Bank Of Montreal Can reported 2,534 shares or 0% of all its holdings. The California-based Franklin Resource Incorporated has invested 0.03% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Shinko Asset Com Ltd last reported 0.03% of its portfolio in the stock. California State Teachers Retirement Systems last reported 105,084 shares in the company. Pnc Services Group Incorporated has 328 shares for 0% of their US portfolio. Ls Advsr Limited Liability Corp reported 1,965 shares or 0% of all its holdings. Bridgeway Cap Management accumulated 0.01% or 42,650 shares. Teacher Retirement Systems Of Texas has 0% invested in the company for 6,435 shares.

Insider Transactions: Since August 12, 2016, the stock had 0 buys, and 14 insider sales for $11.13 million net activity. Zhao Hong sold $421,605 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Friday, August 12. Blobel Friedhelm sold $371,892 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) on Thursday, October 27. Xie Lan had sold 32,832 shares worth $340,221. Another trade for 7,802 shares valued at $82,837 was made by Cheung Wilson Wai-Shun on Friday, August 12. 48,667 shares were sold by King Robert, worth $506,623 on Friday, August 12. $323,574 worth of shares were sold by Meng Chuncai on Friday, August 12. The insider CHANG NANCY T sold 25,040 shares worth $257,896.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $525.88 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.69 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

More recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on October 28, 2009. Also Prnewswire.com published the news titled: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On …” on October 25, 2016. Quotes.Wsj.com‘s news article titled: “DOW JONES, A NEWS CORP COMPANY” with publication date: February 12, 2011 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>